Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term gemcitabine. Found 20 abstracts

Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Bhattacharjee V, Zhou Y, Yen T. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell cycle (Georgetown, Tex). 2014 Jan;13(24):3839-56.   PMCID: 4615005
Held-Warmkessel J. Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Oncol Nurs Forum. 2014 Sep;41(5):551-3.   PMCID: No NIH funds
Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger). Annals of Oncology. 2013 Jan;24(1):257-63.   PMCID: not NIH funded
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, MacDonald J, Willett CG. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 <= 90 U/mL and Comparison to the CONKO-001 Trial. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(3):E291-E297.
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, MacDonald J, Willett CG. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 <= 90 U/mL and Comparison to the CONKO-001 Trial. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(3):E291-E297.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular Cancer Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2012 Apr;10(4):502-35.   PMCID: not NIH funded
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. Journal of Clinical Oncology. 2012 Oct;30(28):3545-51.   PMCID: PMC3454772
Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM. Treatment of Advanced Pancreatic Carcinoma with Y-90-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial. Clinical Cancer Research. 2011 Jun;17(12):4091-100.   PMCID: not NIH funded
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB. Randomized Phase II Study of Gemcitabine Plus Radiotherapy Versus Gemcitabine, 5-Fluorouracil, and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma. Journal of surgical oncology. 2010 Jun;101(7):587-92.   PMCID: NIHMS351520
Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS. Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network. 2010 Sep;8(9):972-+.   PMCID: PMC3135380
Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology. 2009 Nov;27(33):5660-9.   PMCID: not NIH funded
Masters GA, Li SG, Dowlati A, Madajewicz S, Langer C, Schiller J, Johnson D. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group Study (E1501). JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):673-8.
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2005 Jan;96(1):67-71.
Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 2005 Jan;96(1):103-7.
Swaby RF, Bhalla KN. Importance of rational pre-clinical development - Gemcitabine comes of age. CANCER BIOLOGY & THERAPY. 2005 Aug;4(8):872-3.
Treat J. Incorporating novel agents with gemicitabine-based treatment of NSCLC. Lung Cancer. 2005 Oct;50:S8-S9.
Garcia AA, Bookman MA, Rodriguez-Rodriguez L, Mutch DG, Look KY. Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies - A Gynecologic Oncology Group study. Investigational New Drugs. 2002 Nov;20(4):383-7.
Witte RS, Ryan LM, Schutt AJ, Carbone PP, Engstrom PF. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Investigational New Drugs. 1998 Jan;16(4):315-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term gemcitabine

gemcitabine chemotherapy paclitaxel adenocarcinoma trial cisplatin cancer survival radiotherapy doxorubicin ca-19-9 NCCN Guidelines phase-ii trial randomized controlled-trial transitional-cell carcinoma curative resection serum pancreatic cancer bladder-cancer NCCN Clinical Practice Guidelines resectable pancreatic-cancer platinum chemoradiation cell lung-cancer phase-iii trial germ-cell tumors plus cisplatin DNA Double-strand break DNA DSB mitomycin-c indiana-university experience preoperative chemoradiation pancreaticoduodenectomy Rad51 foci Overall survival long-term survival platinum-resistant radiosensitization induction Vdr pancreatic-cancer phase-ii novel agents breast-cancer human lactate dehydrogenase nonsquamous carcinomas siRNA screen apoptosis sgn-30 stem-cell transplantation responses extended retroperitoneal lymphadenectomy colorectal-cancer paclitaxel-resistant fam epithelial ovarian-cancer chemosensitization solid tumors ultrasonography 2010 ung pw-j clin oncol-v28 salvage chemotherapy ovarian cancer preoperative biliary drainage Bxpc3 cyclophosphamide topotecan 5-fluorouracil platinum-containing carboplatin Oncology Progression-free survival at 6 months hematologic malignancies 2011 ung p-j natl cancer i-v103-p194 ductal adenocarcinoma plus irinotecan dexamethasone seminoma metastatic pancreatic carcinoma PALA adriamycin thrombocytopenia high-dose plus bevacizumab renal injury cancer-patients 2002 ung p-can j urol-v9-p1637 monoclonal-antibody pam4 radiation-therapy uterine cervix positron-emission-tomography Second-line treatment exisulind radioimmunotherapy nonsmall cell lung laparotomy ductal carcinoma endoscopic retrograde vinflunine critical reassessment soft-tissue sarcomas novel agent lymph-node dissection lung cancer in-hospital mortality breast cancer stage-i seminoma combination chemotherapy intraoperative 2nd-line treatment dose rate dosimetry therapy phase-ii trials Vitamin D receptor VDR chorionic gonadotropin stalled replication fork growth-factor-receptor cooperative-oncology-group full-dose gemcitabine mesenchymal transition bevacizumab angiosarcoma-hemangioendotheliomas-soft tissue sarcoma farnesyltransferase 9-aminocamptothecin concurrent radiation primary peritoneal carcinoma 1993 bruin mjfm-british journal of urology-v71-p336 prognostic-factors HDAC inhibitors multicenter Intermediate endpoint 2006 giorgi u-eur urol-v50-p1038 2002 oo r-can j urol-v9-p1479 expression non-small-cell lung cancer Immunofluorescence IF resection carcinoma randomized-trials phase II trial Advanced urothelial carcinoma chronic inflammation portal-vein confluence disease pancreas cell cycle arrest brentuximab vedotin antibody-drug conjugate-CD30-Hodgkin's lymphoma-MMAE-SGN-35 docetaxel tract streptozotocin non-squamous cell cervical cancer
Last updated on Wednesday, February 05, 2020